Similar articles for PMID: 16651630

Year	Number of Results
1995	3
1996	2
1997	2
1998	2
1999	3
2000	4
2001	2
2002	5
2003	4
2004	4
2005	4
2006	5
2007	6
2008	6
2009	7
2010	4
2011	7
2012	12
2013	6
2014	7
2015	3
2016	5
2017	4
2018	4
2019	8
2020	3
2021	9
2022	13
2023	2
2024	0

1

The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.

Engström K, Willén H, Kåbjörn-Gustafsson C, Andersson C, Olsson M, Göransson M, Järnum S, Olofsson A, Warnhammar E, Aman P. Engström K, et al. Am J Pathol. 2006 May;168(5):1642-53. doi: 10.2353/ajpath.2006.050872. Am J Pathol. 2006. PMID: 16651630 Free PMC article.

2

Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop.

Andersson MK, Göransson M, Olofsson A, Andersson C, Aman P. Andersson MK, et al. BMC Cancer. 2010 Jun 1;10:249. doi: 10.1186/1471-2407-10-249. BMC Cancer. 2010. PMID: 20515481 Free PMC article.

3

The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ.

Göransson M, Andersson MK, Forni C, Ståhlberg A, Andersson C, Olofsson A, Mantovani R, Aman P. Göransson M, et al. Oncogene. 2009 Jan 15;28(2):270-8. doi: 10.1038/onc.2008.378. Epub 2008 Oct 13. Oncogene. 2009. PMID: 18850010

4

Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression.

Göransson M, Elias E, Ståhlberg A, Olofsson A, Andersson C, Aman P. Göransson M, et al. Int J Cancer. 2005 Jul 1;115(4):556-60. doi: 10.1002/ijc.20893. Int J Cancer. 2005. PMID: 15688424 Free article.

5

Abnormal expression of cell cycle regulators in FUS-CHOP carrying liposarcomas.

Olofsson A, Willén H, Göransson M, Engström K, Meis-Kindblom JM, Stenman G, Kindblom LG, Aman P. Olofsson A, et al. Int J Oncol. 2004 Nov;25(5):1349-55. Int J Oncol. 2004. PMID: 15492825

6

DDIT3/CHOP and the sarcoma fusion oncoprotein FUS-DDIT3/TLS-CHOP bind cyclin-dependent kinase 2.

Bento C, Andersson MK, Aman P. Bento C, et al. BMC Cell Biol. 2009 Dec 17;10:89. doi: 10.1186/1471-2121-10-89. BMC Cell Biol. 2009. PMID: 20017906 Free PMC article.

7

Regulatory mechanisms, expression levels and proliferation effects of the FUS-DDIT3 fusion oncogene in liposarcoma.

Åman P, Dolatabadi S, Svec D, Jonasson E, Safavi S, Andersson D, Grundevik P, Thomsen C, Ståhlberg A. Åman P, et al. J Pathol. 2016 Apr;238(5):689-99. doi: 10.1002/path.4700. J Pathol. 2016. PMID: 26865464

8

DDIT3 Expression in Liposarcoma Development.

Kåbjörn Gustafsson C, Engström K, Aman P. Kåbjörn Gustafsson C, et al. Sarcoma. 2014;2014:954671. doi: 10.1155/2014/954671. Epub 2014 Mar 25. Sarcoma. 2014. PMID: 24790523 Free PMC article.

9

Requirement for YAP1 signaling in myxoid liposarcoma.

Trautmann M, Cheng YY, Jensen P, Azoitei N, Brunner I, Hüllein J, Slabicki M, Isfort I, Cyra M, Berthold R, Wardelmann E, Huss S, Altvater B, Rossig C, Hafner S, Simmet T, Ståhlberg A, Åman P, Zenz T, Lange U, Kindler T, Scholl C, Hartmann W, Fröhling S. Trautmann M, et al. EMBO Mol Med. 2019 May;11(5):e9889. doi: 10.15252/emmm.201809889. EMBO Mol Med. 2019. PMID: 30898787 Free PMC article.

10

FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma.

Trautmann M, Menzel J, Bertling C, Cyra M, Isfort I, Steinestel K, Elges S, Grünewald I, Altvater B, Rossig C, Fröhling S, Hafner S, Simmet T, Åman P, Wardelmann E, Huss S, Hartmann W. Trautmann M, et al. Clin Cancer Res. 2017 Oct 15;23(20):6227-6238. doi: 10.1158/1078-0432.CCR-17-0130. Epub 2017 Jun 21. Clin Cancer Res. 2017. PMID: 28637688

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

131 results

Results by year